BNC KOREA, Inc. (KOSDAQ:256840)

Market Cap	223.31B -20.5%
Revenue (ttm)	95.90B +7.5%
Net Income	2.84B -78.7%
EPS	42.00 -78.8%
Shares Out	68.39M
PE Ratio	77.74
Forward PE	n/a
Dividend	70.00 (2.13%)
Ex-Dividend Date	Dec 29, 2025

Volume	407,520
Average Volume	548,727
Open	3,265.00
Previous Close	3,265.00
Day's Range	3,150.00 - 3,290.00
52-Week Range	3,065.00 - 6,310.00
Beta	n/a
RSI	25.46
Earnings Date	Mar 27, 2026

About BNC KOREA

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials in South Korea. The company offers HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, ChungA-an, CUTEGEL-M, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration. It also provides Hibarry, a dressing for deep-cavity wounds that is used to reduce adhesion of the spinal cord during surgery; GENTA Q, a white collagen sponge, which is used to protect w...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 256840

Financial Performance

In 2025, BNC KOREA's revenue was 95.90 billion, an increase of 7.47% compared to the previous year's 89.23 billion. Earnings were 2.84 billion, a decrease of -78.68%.